Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance Shares of GLMD opened at $0.39 on Friday. The stock has a market capitalization of $648,480.00, a P/E ratio […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Cambridge Investment Research Advisors Inc ,Galmed Pharmaceuticals Stock Performance ,Raymond James Financial Services Advisors Inc ,Millennium Management ,Walleye Capital ,Galmed Pharmaceuticals Company Profile ,News Ratings For Galmed Pharmaceuticals Daily ,Galmed Pharmaceuticals ,Galmed Pharmaceuticals Ltd ,Free Report ,Investment Research Advisors ,James Financial Services Advisors ,Get Free Report ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,